Literature DB >> 22177875

What we have learned: the impact of quality from a clinical trials perspective.

Thomas J FitzGerald1.   

Abstract

In this review article, we address the radiation oncology process improvements in clinical trials and review how these changes improve the quality for the next generation of trials. In recent years, we have progressed from a time of limited data acquisition to the present in which we have real-time influence of clinical trials quality. This enables immediate availability of the important elements, including staging, eligibility, response, and outcome for all trial investigators. Modern informatics platforms are well designed for future adaptive clinical trials. We review what will be needed in the informatics architecture of current and future clinical trials.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2012        PMID： 22177875      PMCID： PMC3244686          DOI： 10.1016/j.semradonc.2011.09.004

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN： 1053-4296            Impact factor:   5.934


  40 in total

1.  Credentialing of institutions for IMRT in clinical trials.

Authors:  Jatinder R Palta; James A Deye; Geoffrey S Ibbott; James A Purdy; Marcia M Urie
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-07-15       Impact factor: 7.038

2.  What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract?

Authors:  C A Arndt; S S Donaldson; J R Anderson; R J Andrassy; F Laurie; M P Link; R B Raney; H M Maurer; W M Crist
Journal:  Cancer       Date:  2001-06-15       Impact factor: 6.860

3.  Impact of a dosimetry review program on radiotherapy in group trials.

Authors:  L E Reinstein; S Peachey; F Laurie; A S Glicksman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1985-06       Impact factor: 7.038

4.  Quality assurance of radiotherapy in clinical trials.

Authors:  A S Glicksman; L E Reinstein; F Laurie
Journal:  Cancer Treat Rep       Date:  1985-10

5.  Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803--a report from the Children's Oncology Group.

Authors:  Chi Lin; Sarah S Donaldson; Jane L Meza; James R Anderson; Elizabeth R Lyden; Christopher K Brown; Karen Morano; Fran Laurie; Carola A Arndt; Charles A Enke; John C Breneman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-04       Impact factor: 7.038

6.  Technical structure of a radiotherapy protocol.

Authors:  L E Reinstein; A S Glicksman; F Laurie
Journal:  Eur J Cancer Clin Oncol       Date:  1987-06

7.  An evaluation of the relationship between the quality of prophylactic cranial radiotherapy in childhood acute leukemia and institutional experience: a Quality Assurance Review Center-Pediatric Oncology Group study.

Authors:  Edward C Halperin; Fran Laurie; T J Fitzgerald
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-07-15       Impact factor: 7.038

8.  Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV.

Authors:  Jeff M Michalski; Jane Meza; John C Breneman; Suzanne L Wolden; Fran Laurie; MaryAnn Jodoin; Beverly Raney; Moody D Wharam; Sarah S Donaldson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-07-15       Impact factor: 7.038

9.  Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: a report from The Intergroup Rhabdomyosarcoma Study-IV, 1991-1997.

Authors:  R Beverly Raney; Julie A Stoner; David O Walterhouse; Richard J Andrassy; Sarah S Donaldson; Fran Laurie; William H Meyer; Stephen J Qualman; William M Crist
Journal:  Pediatr Blood Cancer       Date:  2004-06       Impact factor: 3.167

10.  Current calibration, treatment, and treatment planning techniques among institutions participating in the Children's Oncology Group.

Authors:  Marcia Urie; T J FitzGerald; David Followill; Fran Laurie; Robert Marcus; Jeff Michalski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-01-01       Impact factor: 7.038
View more
  5 in total

1.  Quantifying Unnecessary Normal Tissue Complication Risks due to Suboptimal Planning: A Secondary Study of RTOG 0126.

Authors:  Kevin L Moore; Rachel Schmidt; Vitali Moiseenko; Lindsey A Olsen; Jun Tan; Ying Xiao; James Galvin; Stephanie Pugh; Michael J Seider; Adam P Dicker; Walter Bosch; Jeff Michalski; Sasa Mutic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-03       Impact factor: 7.038

2.  Credentialing for participation in clinical trials.

Authors:  David S Followill; Marcia Urie; James M Galvin; Kenneth Ulin; Ying Xiao; Thomas J Fitzgerald
Journal:  Front Oncol       Date:  2012-12-26       Impact factor: 6.244

3.  Development of a multicentre automated model to reduce planning variability in radiotherapy of prostate cancer.

Authors:  Vanessa Panettieri; David Ball; Adam Chapman; Nigel Cristofaro; Janet Gawthrop; Peter Griffin; Sisira Herath; Susan Hoyle; Liam Jukes; Tomas Kron; Cathy Markham; Loretta Marr; Phillip Moloney; Flavio Nelli; Prabhakar Ramachandran; Amanda Smith; Colin J Hornby
Journal:  Phys Imaging Radiat Oncol       Date:  2019-08-08

4.  Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial.

Authors:  Egilius L H Spierings; Mikko Kärppä; Xiaoping Ning; Joshua M Cohen; Verena Ramirez Campos; Ronghua Yang; Uwe Reuter
Journal:  J Headache Pain       Date:  2021-04-16       Impact factor: 7.277

Review 5.  Radiation Oncology: Future Vision for Quality Assurance and Data Management in Clinical Trials and Translational Science.

Authors:  Linda Ding; Carla Bradford; I-Lin Kuo; Yankhua Fan; Kenneth Ulin; Abdulnasser Khalifeh; Suhong Yu; Fenghong Liu; Jonathan Saleeby; Harry Bushe; Koren Smith; Camelia Bianciu; Salvatore LaRosa; Fred Prior; Joel Saltz; Ashish Sharma; Mark Smyczynski; Maryann Bishop-Jodoin; Fran Laurie; Matthew Iandoli; Janaki Moni; M Giulia Cicchetti; Thomas J FitzGerald
Journal:  Front Oncol       Date:  2022-08-10       Impact factor: 5.738
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.